3/20
11:12 am
dsgn
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Medium
Report
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
3/20
11:12 am
dsgn
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Medium
Report
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
3/20
10:56 am
dsgn
Rating for DSGN
Medium
Report
Rating for DSGN
3/20
10:56 am
dsgn
Rating for DSGN
Medium
Report
Rating for DSGN
3/20
10:36 am
dsgn
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/20
10:36 am
dsgn
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Design Therapeutics, Inc. (NASDAQ: DSGN) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/20
10:34 am
dsgn
Rating for DSGN
High
Report
Rating for DSGN
3/20
10:34 am
dsgn
Rating for DSGN
High
Report
Rating for DSGN